SCHEMBL6037614

SCHEMBL6037614

Cn1c(S)nc2scc(-c3ccccc3)c2c1=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.57
▸ GAA P10253 1/20 0.57
▸ ALDH1A1 P00352 8/20 0.56
▸ HSD17B10 Q99714 3/20 0.56
▸ MAPK1 P28482 2/20 0.56
▸ ALOX15 P16050 1/20 0.56
▸ TGM2 P21980 2/20 0.55
▸ HTT P42858 3/20 0.54
▸ TSHR P16473 1/20 0.52
▸ RAB9A P51151 2/20 0.47
▸ PPARG P37231 1/20 0.47
▸ OPRK1 P41145 1/20 0.47
▸ NCOA1 Q15788 1/20 0.47
▸ APOBEC3G Q9HC16 1/20 0.47
▸ LMNA P02545 2/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ KDM4E B2RXH2 3/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6034875 0.82 TGM2 (0.56) MAPTGAAALDH1A1HSD17B10MAPK1
SCHEMBL6033928 0.79 TGM2 (0.59) MAPTGAAALDH1A1HSD17B10MAPK1
SCHEMBL6034870 0.79 TGM2 (0.60) MAPTGAAALDH1A1HSD17B10MAPK1
SCHEMBL6034127 0.78 TGM2 (0.58) MAPTGAAALDH1A1HSD17B10MAPK1
SCHEMBL6034224 0.77 TGM2 (0.59) MAPTGAAALDH1A1HSD17B10MAPK1
SCHEMBL6034377 0.77 TGM2 (0.50) MAPTGAAALDH1A1HSD17B10MAPK1
SCHEMBL6034382 0.77 TGM2 (0.59) MAPTGAAALDH1A1HSD17B10MAPK1
SCHEMBL6034917 0.77 TGM2 (0.59) MAPTGAAALDH1A1HSD17B10MAPK1
SCHEMBL6033990 0.77 TGM2 (0.61) MAPTGAAALDH1A1HSD17B10MAPK1
SCHEMBL6034346 0.77 MAPK1 (0.63) MAPTGAAALDH1A1HSD17B10MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060183759-A1 Tissue transglutaminase inhibitors BRIGHAM AND WOMEN'S HOSPITAL, INC., THE 2006-08-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183759-A1 Tissue transglutaminase inhibitors TGM2, HNMT, TPMT MAPT 40/4885GAA 42/4885ALDH1A1 3116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback